Bethesda-based Sucampo named former MedImmune president Peter Greenleaf to serve as the company’s chief executive starting next month, according to a news release.
The appointment brings a high-profile name to the biotechnology firm as it looks to commercialize products for glaucoma and constipation, as well as develop additional drugs to treat eye and digestive issues.
{iframe}http://www.washingtonpost.com/business/capitalbusiness/sucampo-names-peter-greenleaf-to-chief-executive-post/2014/02/10/6dc0ec6e-929a-11e3-84e1-27626c5ef5fb_story.html{/iframe}